Abstract:Introduction: Growing evidence suggests a link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded RV, and mortality in pulmonary arterial hypertension (PAH). However, there are no currently available therapies that specifically target RV fibrosis. Using RV tissues from a preclinical rat PAH model, we previously reported that activation of stress-responsive protein kinase D (PKD) and phosphorylation of its substrate dynamin-related protein 1 (DRP1) occur specifically at the outer mitochondrial membrane (OMM) of RV cardiac fibroblasts (RV-CFs), but not in RV myocytes. RV-CFs isolated from PAH rats exhibited increased mitochondrial fission, mitochondrial reactive oxygen species (mROS), and proliferative signaling compared to RV-CFs from control animals, suggesting an association between PKD signaling in RV-CFs and RV fibrosis. Hypothesis: Inhibition of mitochondrial PKD signaling in CFs can attenuate RV fibrosis in PAH. Methods: Primary adult CFs from human ventricles were used for in vitro assays. A preclinical rat PAH model (Sugen 5416 injection and 3-week hypoxia followed by 4-week normoxia) was used for in vivo assays. Results: To specifically inhibit PKD activity at the OMM, an OMM-targeted dominant-negative PKD1 (mt-PKD-DN) was generated by adding an OMM-target sequence (amino acid 1-33 from human TOM20) at the N-terminus of PKD1-K612W. We confirmed that mt-PKD-DN is specifically expressed in mitochondria and decreases basal PKD activity only in mitochondria, assessed by protein fractionation. Importantly, mt-PKD-DN was able to inhibit mitochondrial fission, reduce mROS, hyperpolarize mitochondrial membrane potential, and ultimately decrease CF proliferation in vitro. To inhibit mitochondrial PKD activity in quiescent and resident CFs in vivo, we next administrated CF-selective adeno-associated virus serotype 9 (AAV9) carrying human TCF21 (hTCF21) promoter and mt-PKD-DN into the rat PAH model by tail vein injection. Introduction of AAV9-hTCF21-mt-PKD-DN or its control virus did not significantly alter baseline cardiac function. CF-specific mt-PKD-DN expression was able to significantly reduce RV hypertrophy/fibrosis, and RV-CF hyperproliferation as assessed by immunostaining of a nucleus-localized marker of active cell proliferation Ki67. Lastly, we found the partial recovery of in vivo RV function (i.e., recovery of tricuspid annular plane systolic excursion in echocardiography) in PAH rats with mt-PKD-DN. Conclusion: Targeting mitochondrial PKD may be a potential therapeutic strategy to reduce cardiac fibrosis under pathological conditions including PAH. R01HL136757 (to J.O.-U), AHA 18CDA34110091 (to B.S.J) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Abstract 12004: Mitochondrial Fission Mediator MiD49 Regulates Proliferation via MYO1C in Pulmonary Arterial Hypertension

Abstract 15702: Role of the Drp-1 Receptors Mid49 and Mid51 in Regulating Fission and Cell Proliferation in Pulmonary Arterial Hypertension

Abstract 15168: The Role of Mitochondrial Fission Factor (MFF) and Increased Midzone Mitochondrial Fission in Pulmonary Arterial Hypertension: Implications for Proliferation, Mitophagy, and Apoptosis

CircGSAP regulates the cell cycle of pulmonary microvascular endothelial cells via the miR-942-5p sponge in pulmonary hypertension

Role of Dynamin 2 in mitochondrial fission and cell cycle regulation: Dysregulation of a miR-124-3p-STAT3-DNM2-Drp1-RGCC pathway connects fission and cell proliferation in pulmonary arterial hypertension

Human pulmonary artery smooth muscle cell dysfunction is regulated by miR-509-5p in hypoxic environment

ERK/Drp1‐dependent mitochondrial fission contributes to HMGB1‐induced autophagy in pulmonary arterial hypertension

Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension

Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2

The Role of Mitochondrial Dynamics and Mitotic Fission in Regulating the Cell Cycle in Cancer and Pulmonary Arterial Hypertension: Implications for Dynamin-Related Protein 1 and Mitofusin2 in Hyperproliferative Diseases

Role of mitochondrial PKD on right ventricular fibrosis under pulmonary hypertension

Microrna-124 Suppresses The Transactivation Of Nuclear Factor Of Activated T Cells By Targeting Multiple Genes And Inhibits The Proliferation Of Pulmonary Artery Smooth Muscle Cells

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension

Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension

Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increased Mitochondrial Fission In Vitro and Atherosclerosis in High-Fat-Diet-Fed ApoE-/- Mice

STAT3 phosphorylation at Tyr705 affects DRP1 (dynamin-related protein 1) controlled-mitochondrial fission during the development of apoptotic-resistance in pulmonary arterial endothelial cells

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension Via Mtorc1 Signaling

CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension

PARM1 Drives Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension via AKT/FOXO3A Axis

Ubiquitinated AIF is a major mediator of hypoxia-induced mitochondrial dysfunction and pulmonary artery smooth muscle cell proliferation

JMJD1C promotes smooth muscle cell proliferation by activating glycolysis in pulmonary arterial hypertension